2020 ICD-10-CM Diagnosis Code C61

Malignant neoplasm of prostate

    2016 2017 2018 2019 2020 Billable/Specific Code Male Dx
  • C61 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2020 edition of ICD-10-CM C61 became effective on October 1, 2019.
  • This is the American ICD-10-CM version of C61 - other international versions of ICD-10 C61 may differ.
ICD-10-CM Coding Rules
  • C61 is applicable to male patients.
Use Additional
Use Additional Help
Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions the ICD-10-CM has a coding convention that requires the underlying condition be sequenced first followed by the manifestation. Wherever such a combination exists there is a "use additional code" note at the etiology code, and a "code first" note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation. In most cases the manifestation codes will have in the code title, "in diseases classified elsewhere." Codes with this title are a component of the etiology/manifestation convention. The code title indicates that it is a manifestation code. "In diseases classified elsewhere" codes are never permitted to be used as first listed or principle diagnosis codes. They must be used in conjunction with an underlying condition code and they must be listed following the underlying condition.
  • code to identify:
  • hormone sensitivity status (
    ICD-10-CM Diagnosis Code Z19.1

    Hormone sensitive malignancy status

      2017 - New Code 2018 2019 2020 Billable/Specific Code POA Exempt
    Z19.1-
    ICD-10-CM Diagnosis Code Z19.2

    Hormone resistant malignancy status

      2017 - New Code 2018 2019 2020 Billable/Specific Code POA Exempt
    Applicable To
    • Castrate resistant prostate malignancy status
    Z19.2
    )
  • rising PSA following treatment for malignant neoplasm of prostate (
    ICD-10-CM Diagnosis Code R97.21

    Rising PSA following treatment for malignant neoplasm of prostate

      2017 - New Code 2018 2019 2020 Billable/Specific Code Adult Dx (15-124 years) Male Dx Questionable As Admission Dx
    R97.21
    )
Type 1 Excludes
Type 1 Excludes Help
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as C61. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
  • malignant neoplasm of seminal vesicle (
    ICD-10-CM Diagnosis Code C63.7

    Malignant neoplasm of other specified male genital organs

      2016 2017 2018 2019 2020 Billable/Specific Code Male Dx
    Applicable To
    • Malignant neoplasm of seminal vesicle
    • Malignant neoplasm of tunica vaginalis
    C63.7
    )
The following code(s) above C61 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C61:
  • C00-D49
    2020 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • C60-C63
    2020 ICD-10-CM Range C60-C63

    Malignant neoplasms of male genital organs

    Includes
    • malignant neoplasm of skin of male genital organs
    Malignant neoplasms of male genital organs
Approximate Synonyms
  • Adenocarcinoma of prostate
  • Cancer of prostate with metastasis to eye
  • Cancer of the prostate
  • Cancer of the prostate with metastasis
  • Cancer of the prostate, adenocarcinoma
  • Cancer of, prostate, hormone refractory
  • Carcinoma of prostate
  • Hormone refractory prostate cancer
  • Metastasis from malignant tumor of prostate
  • Prostate cancer metastatic to eye
  • Recurrent prostate cancer
Clinical Information
  • A primary or metastatic malignant tumor involving the prostate gland. The vast majority are carcinomas.
  • The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, being african-american, and some genetic changes.symptoms of prostate cancer may include
    • problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling
    • low back pain
    • pain with ejaculation
    your doctor will diagnose prostate cancer by feeling the prostate through the wall of the rectum or doing a blood test for prostate-specific antigen (psa). Other tests include ultrasound, x-rays, or a biopsy.treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments. nih: national cancer institute
ICD-10-CM C61 is grouped within Diagnostic Related Group(s) (MS-DRG v37.0):
  • 715 Other male reproductive system o.r. Procedures for malignancy with cc/mcc
  • 716 Other male reproductive system o.r. Procedures for malignancy without cc/mcc
  • 722 Malignancy, male reproductive system with mcc
  • 723 Malignancy, male reproductive system with cc
  • 724 Malignancy, male reproductive system without cc/mcc

Convert C61 to ICD-9-CM

Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
Code annotations containing back-references to C61:
  • Code First: Z79.81
    ICD-10-CM Diagnosis Code Z79.81

    Long term (current) use of agents affecting estrogen receptors and estrogen levels

      2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
    Code First
    • , if applicable:
    • malignant neoplasm of breast (C50.-)
    • malignant neoplasm of prostate (C61)
    Type 1 Excludes
    • hormone replacement therapy (Z79.890)
    Use Additional
    • code, if applicable, to identify:
    • estrogen receptor positive status (Z17.0)
    • family history of breast cancer (Z80.3)
    • genetic susceptibility to malignant neoplasm (cancer) (Z15.0-)
    • personal history of breast cancer (Z85.3)
    • personal history of prostate cancer (Z85.46)
    • postmenopausal status (Z78.0)
  • Type 2 Excludes: N40
    ICD-10-CM Diagnosis Code N40

    Benign prostatic hyperplasia

      2016 2017 - Revised Code 2018 2019 2020 Non-Billable/Non-Specific Code
    Includes
    • adenofibromatous hypertrophy of prostate
    • benign hypertrophy of the prostate
    • benign prostatic hypertrophy
    • BPH
    • enlarged prostate
    • nodular prostate
    • polyp of prostate
    Type 1 Excludes
    • benign neoplasms of prostate (adenoma, benign) (fibroadenoma) (fibroma) (myoma) (D29.1)
    Type 2 Excludes
    • malignant neoplasm of prostate (C61)

Diagnosis Index entries containing back-references to C61:

ICD-10-CM Codes Adjacent To C61
C57.7 Malignant neoplasm of other specified female genital organs
C57.8 Malignant neoplasm of overlapping sites of female genital organs
C57.9 Malignant neoplasm of female genital organ, unspecified
C58 Malignant neoplasm of placenta
C60 Malignant neoplasm of penis
C60.0 Malignant neoplasm of prepuce
C60.1 Malignant neoplasm of glans penis
C60.2 Malignant neoplasm of body of penis
C60.8 Malignant neoplasm of overlapping sites of penis
C60.9 Malignant neoplasm of penis, unspecified
C61 Malignant neoplasm of prostate
C62 Malignant neoplasm of testis
C62.0 Malignant neoplasm of undescended testis
C62.00 Malignant neoplasm of unspecified undescended testis
C62.01 Malignant neoplasm of undescended right testis
C62.02 Malignant neoplasm of undescended left testis
C62.1 Malignant neoplasm of descended testis
C62.10 Malignant neoplasm of unspecified descended testis
C62.11 Malignant neoplasm of descended right testis
C62.12 Malignant neoplasm of descended left testis
C62.9 Malignant neoplasm of testis, unspecified whether descended or undescended

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.